GLP1减重宝典·2025-08-02 08:33Core Viewpoint - The strategic partnership between Borui Pharmaceutical and China Resources Sanjiu aims to advance the development and commercialization of the GLP-1/GIP dual-target agonist BGM0504 injection in mainland China, with a milestone funding of up to 282 million RMB for clinical trials [2][4]. Group 1: Product Development - BGM0504 is a self-developed dual agonist targeting GLP-1 and GIP receptors, showing synergistic effects in blood sugar control, weight management, and treatment of non-alcoholic fatty liver disease (NASH) [2]. - The product has demonstrated superior efficacy in Phase II clinical trials compared to the single-target drug Semaglutide, covering three major areas: type 2 diabetes, weight loss, and NASH, indicating a significant market potential [4]. - Currently, BGM0504 is undergoing three Phase III clinical trials in China and one in Indonesia, with the weight loss indication already having received IND approval in the U.S. [4]. Group 2: Future Prospects - An oral formulation of BGM0504 is in the preclinical stage, which may overcome existing limitations of GLP-1 class drugs regarding administration routes [4]. - The Phase III clinical trials in China are in the patient enrollment and follow-up stages, with expectations to enter the market application process between 2025 and 2026 [4].